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ABSTRACT
A double blind placebo controlled, 4-way crossover
study was carried out to investigate the 
pharmacokinetics of single oral doses of xipamide
(lOmg), triamterene (30mg) and Trirexan <10mg xipamide + 
30mg triamterene) in a group of 12 healthy male 
volunteers. HPLC assays were developed for the
measurement of both drugs in plasma. Plasma levels of
xipamide and triamterene were measured using these 
validated HPLC methods. The individual plasma level 
data are presented as tables and the mean plasma levels 
are presented graphically. Plasma xipamide levels 
measured over a 24 hour period after dosing with
xipamide alone and in a fixed combination as Trirexan 
were analysed using the JANA curve stripping program. 
The estimates of the pharmacokinetic parameters thus 
obtained were then used in curve fitting analysis using 
an IBM-PC compatible version of NONLIIT 84. Plasma 
triamterene levels after dosing with triamterene and 
Trirexan were likewise analysed.
2
CONTENTS 
PART I
FAGE
1. TITLE ....................... 1
2. CONTENTS ...................... 3
3. INTRODUCTION ......................  7
4. CHROMATOGRAPHIC TECHNIQUE.......... 12
HPLC ...................  13
GC ....................... 29
5. COMPETITIVE PROTEIN BINDING
ASSAYS ..........................  41
RADIOIMMUNOASSAY...........  42
ENZYME IMMUNOASSAY.........  43
FLUORESCENCE IMMUNOASSAY. . . 44
MONOCLONAL ANTIBODIES.....  44
6. POLAROGRAPHY......................... 45
PART II
1. TITLE ................................ 48
2. SUMMARY..............................  49
3. XIPAMIDE ASSAY......................  57
4. PLASMA XIPAMIDE LEVELS.............  70
5. TRIAMTERENE ASSAY................... 78
6. PLASMA TRIAMTERENE LEVELS.......... 96
7. PHARMACOKINETIC ANALYSIS.......... 102
8. RESULTS.............................  139
3
ACKNOWLEDGEMENTS
I wish to express my thanks to :-
The Institute of Clinical Pharmacology for allowing me 
the facilities to carry out this project and for their 
support throughout the two years of the course.
The staff of the Institute in particular the staff of 
the analytical laboratory for their assistance and 
advice.
My supervisor Dr. Dariosh Dadgar for his excellent 
advice, assistance and continuous encouragement
throughout this project and during the course.
Dr. Ronan Lambe for his continuous support.
Dr. Malda Guidensie of Degussa Pharma for allowing me to 
use data from their study.
Finally my wife Olive and children David and Rachel for 
their help , support and encouragement but most 
importantly for putting up with me throughout the two 
years of this course.
4
DEDICATED TO DENISE
RECENT ADVANCES IN BIOPHARMACEUTICAL ANALYSIS
6
INTRODUCTION
Biopharmaceutical analysis is the analysis of drugs and 
their metabolites in biological fluids. There are a 
number of reasons why it is important to measure drug 
levels in such samples. Before a new drug can be 
administered to patients it is necessary that it be 
rigorously tested in a number of animal species followed 
by testing in normal healthy volunteers. As well as 
measuring parent drug levels in tissues , blood , urine 
and faeces it is also necessary to measure levels of the 
drug metabolites which may also be present. While it is 
generally assumed that drug metabolites are inactive and 
more readily excreted by the kidneys than the parent 
drug there are many examples of drugs whose metabolites 
are active or even toxic <1). Major inactive metabolites 
although they may not be of clinical importance may be 
of extreme importance from an analytical point of view 
as they may interfere with drug assay methods because of 
structural similarity with the parent compound. Careful 
control of the analytical conditions can allow for 
seperation of structurally similar compounds in some 
assay systems. It may not however always be possible to 
alter assay conditions to allow differentiation between 
parent drug and structurally similar compounds. In 
radioimmunoassay for example the specificity of the
•7
antibody determins the specificity of the assay.
New formulation procedures and drug delivery systems are 
continuously being developed and it is necessary to 
monitor drug levels in order to demonstrate 
bioequivalence with standard formulations which have 
been in use and found to be effective. Associated with 
these developements in pharmaceutical research, 
pharmacokinetics and pharmacodynamics as well as drug 
metabolism have become established as scientific 
disciplines in their own right. Clinical
pharmacokinetics has been discribed as ” a health 
science discipline which deals with the application of 
pharmacokinetics to the safe and effective therapeutic 
management of the individual patient ” (2) . The large 
inter subject variations which occur in response to 
drugs are apparent to all who work in this field and 
often optimisation of individual dosage regimens is only 
possible after close monitoring of plasma drug level 
data.
The illicit use of drugs has become a major worldwide 
problem and the use of definative assays for drugs in 
biological fluids and other materials in forensic 
science departments has grown in line with the drug 
abuse problem. For obvious reasons it is extremely 
important that the methods used in this area need to be
highly specific , very reproducible and rapid (suspects 
can invariably only be held in custody for short periods 
of time ) .
Many of the methods that have been developed are used to 
detect trace quantities of drug in the very small 
amounts of biological materials which are available <3).
A variety of analytical techniques are used in clinical 
laboratories for the measurement of drugs in biological 
materials. Chromatographic techniques using a variety of
detection systems, spectroscopic analysis and 
competitive protein binding asseys have been most 
frequently employed. Drug level monitering is based on 
analytical techniques suitable for the quantitative 
detection of drugs and their metabolites in biological
samples. A survey of the analytical techniques for drug 
analysis in biological samples published in the
litrature will reveal a long list of techniques. These
include:-
High performance liquid chromatography CHPLC)
Gas chromatography CGC)
Mass spectrometry (MS)
Combinations of HPLC and GC with Mass spectrometry 
Thin layer chromatography (TLC)
Ultraviolet spectrophotometry.
Flourescence spectrophotometry.
Colorimetry.
Polarography.
Radioimmunoassay (RIA).
Enzyme immunoassay (EIA,ELISA and EMIT).
Protein binding assays.
Microbiological assays.
The current trend is undoubtedly directed towards even 
more sensitive, specific and reproducibal techniques for 
the quantitation of drugs and their metabolites in 
biological specimens.
The measurement of drugs and their intermediates in 
fermentation broths and during chemical synthesis are 
other areas where the methods used in biopharmacutical 
science can be applied, this area is however considered 
to be outside the scope of this review.
The most commonly used metods will be reviewed in turn 
with specific emphasis on new developments,
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CHROMATOGRAPHIC TECHNIQUES.
Chromatographic techniques (HPLC , GC AND TLC) combined 
with a variety of detection systems are the most widely 
used for drug measurements in biological materials. This 
has been brought about by the availability of sensitive 
and selective detection systems as well as significant 
advances in column technology (4). The recent popularity 
of HPLC assays for drugs in biological samples is based 
on the versatility, sensitivity, specificity and speed 
of the technique. Reverse phase packing materials show 
great potential for the analysis of drugs in biological 
materials, as polar compounds elute quickly and do not 
therefore interfere with the analysis of lipophilic 
drugs. Most drugs are by design weak electrolytes with 
varying molecular weights. Metabolic transformation of 
these compounds generally results in the formation of 
metabolites having increased polarity and decreased 
lipophicity. It is in the simultaneous measurement of 
drugs and their metabolits that chromatographic methods 
realise their greatest potential. The chrometographic 
techniques which will be considered here are HPLC and
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RECENT- DEVELOPMENTS LN HPLC 
MICROBORE COLUMNS
The last ten years have seen many publications and much 
discussion on microbore columns. Three types of column 
have been discribed, narrow bore packed <5,6), 
microcapillary packed and open tubular <7,8). These 
publications have quoted internal diameters ranging from 
10 u to 2 mm. The terminology has become further 
confused by the use of additional terms such as low 
dispersion liquid chromatography <LDLC), fast microbore 
and capillary liquid chromatography.
Although there are a large number of reports of the 
advantages of this type of chromatography <5,6,7,8 and 
9) their use for routine pharmaceutical analysis has not 
been as widespread as might be expected. One reason for 
this is that microbore LC is not compatible with all 
conventional HPLC Systems. This situation will be 
improved by the development of new equipment which is 
compatible with both conventional and microbore 
technology. Many conventional HPLC systems may also be 
adapted at minimal cost to accomodate microbore columns 
<10). The main advantages associated .pa with the use of 
microbore columns are the considerable reduction in 
running costs that can be achieved by the use of low
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solvent flow rates and smaller amounts of column packing 
materials, the high effeciencies and mass sensitivities 
that can be achieved and the fact that the low flow 
rates used make the coupling of liquid chromatography
with mass spectrometry as a detection system a much 
easier proposition <11). Like any analytical technique 
micro column HPLC is not without it's difficulties, 
these include the necessity for low dead volume injector 
and detector systems, difficulties associated with 
packing of such columns and column overload when too
large a sample is injected onto the column.
Apart from the economic advantages of narrow bore HPLC 
there are three other general areas where advances are 
being made. These include increased mass sensitivity, 
linking of columns to give high plate counts and the
application of new detection systems which are made 
possible because of the low flow rate. The most 
interesting of these are flame based detectors which in 
general have little application in biopharmaceutical 
analysis and mass spec. detectors.The potential 
increases in mass sensitivity may not always be 
achieveable in practice however and the difficulties in 
achieveing the theoretical improvements are outlined by 
Gill in his article on the subject (12). Briefly for UV 
detectors using small volume flow cells e.g. 0.5ul. the
theoretically expected improvements will be seen when 
reducing the column bore.Vith electrochemical detectors 
flow cell volumes of down to In litre have been
described (13). and the use of these detectors would be 
expected to produce massive increases in .pa
sensitivity, however, the flow rate in such detectors 
also affects the performance and increases of 5-6 fold 
are as much as are achieveable in practice with such 
systems <12).
Experimental work with microbore columns has shown that 
coupling of a number of such columns can result in great 
increases in plate count. For example greater than
40,000 theoretical plates at optimum velocity has been 
quoted (12). Such high plate counts can be useful in the
analysis of complex mixtures of drugs in biological
fluids and are particularly useful in forensic work.
INTERNAL SURFACE REVERSE PHASE COLUMNS
As recently reported the development by Prof. T.
Pinkerton of Purdue University , Indiana, of HPLC
columns which allow for the direct injection of serum 
samples has greaty reduced the sample preparation
time for pharmaceutical analysis (14). Injection of 
serum directly on to conventional columns is not
possible and removal of protein by some mechanism such
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as percipitation or on or off line solid phase 
extraction is necessary. If these precautions are not 
taken back pressure quickly builds up and further 
analysis is not possible. The developement of a new
packing material called internal surface reverse phase 
(IRSP) allows for direct injection of untreated serum or 
plasma or other protein containing materials. 
Conventional silica particles are derivitised with 
glycerylpropyl groups forming a bonded hydrophilic phase 
that is non adsorbtive to protein. To provide the
hydrophobic partitioning phase that is also needed, 
polypeptides such as glycine-l-phenylalanine-1-. pa 
phenylalanine are covalently bonded to the glyceropropy1 
groups. The derivitised silica is then treated with 
carboxypeptidase which cleaves the phenylalanine 
moieties from the external surface of the particles but 
not from the internal surfaces as it cannot enter the 
particles on account of it's size. When serum samples 
are injected on to these ISRP columns the proteins do 
not adsorb on to the external surfaces and elute 
rapidly. The analytes do however penetrate the internal
surfaces and interact with the polypeptides. Tests of
this new packing material have shown that as many as 240 
direct injections were passible without the build up of 
excessive back pressure. This development has been 
licenced to a manufacturing company in the United States
of America who are currently adapting the idea for mass 
production and developing applications methodology.
CARTRIDGE COLUMN SYSTEMS
Many companies have now produced cartridge columns 
which allow for the insertion of prepacked cartridges 
into HPLC assemblies. This allows different lengths of 
column to be inserted into the HPLC system and thus 
reduce column cost and solvent consumdption Low cost, 
easily interchangeable columns are ideal for method 
development. It is possible to have on hand a wide 
variety of packing materials e.g. 3 centimetre columns 
for method development . When a suitable solvent has 
been selected and higher resolution is required a longer 
cartridge with the same packing material is chosen (15).
Most laboratories spend more per year on HPLC grade 
solvents than they do on columns. The use of cartridge 
systems allow for the use of 2.1mm internal diameter 
microbore columns with conventional HPLC appparatus. 
These microbore systems use only 20% of the solvent that 
a normal 4.6mm internal diameter column would use.
These modular column systems are connected into the HPLC 
using finger tightened couplings which it is claimed 
will not leak at pressures of up to 7000 psi. These
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couplings allow for direct connection of two or more 
columns this has the advantage that seperations can be 
achieved using combinations of columns that could not be 
achieved with any of the columns on their own.
DETECTOR SYSTEMS
The function of any detector is to measure accurately 
the concentration or amount of the sample components 
eluted from the column and generally the following
requrements are necessary
(a) ability to detect lppm or less of solute 
<b) no remixing of components as they pass through the 
detector
(c) a wide linear dynamic range to ensure that
quantative analysis can take place in a straight­
forward manner.
Detector characterstics have been covered in detail by 
Scott. (15). The most important parameters being low 
noise, high sensitivity and wide linear response.
The detector type most commonly used in 
biopharmaceutical analysis is the UV or UV/visable
detector. For highly absorbing species a detection limit 
of as low lng/ml may be achieved but generally a limit 
of detection of 5-10 ng/ml would be considered good for
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The original UV detectors were fixed wavelength 
detectors. Low pressure mercury lamps were used to give 
a series of discreet wavelengths and 254 nm was very 
commonly used. More modern detectors use deuterium lamps 
which provide a continous source and used in conjunction 
with good quality filters, species absorbing in the 
range 180-400 nm can be detected.
The improvements that have taken place in microcomputer 
technology over the past few years have led to a new 
breed of rapid scanning UV spectrophotometers that 
permit simultanious multiwavelength detection. These 
detectors are based on optical multichannel analysers 
that use either a silicon intensified vidicon tube (SIT) 
or a linear diode array (LDA) for the rapid capture of 
UV light (16).
An alternative approach is the use of a microprocessor 
controlled variable wavelength detector which will 
monitor the absorbtion at a specific wavelength for a 
pre-programmed amount of time, then switch to another 
wavelength re zero the instrument and monitor absorbtion 
at that new wavelength. This will allow for the 
simultaneous measurement of a number of compounds with 
markedly different absorbtion maxima in a single assay.
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PIEZOELECTRIC CRYSTAL DETECTION SYSTEMS
A voltage can be obtained from some materials e.g. 
quartz crystals and certain ceramics by compressing 
them. Conversely if a voltage is appllied to these 
materials the crystal expands or contracts. This is
known as the piezoelectric effect. Recently several
groups of workers have tried to link these types of 
device to HPLC systems. Some pleminary work has been 
reported on the applications of piezoelectric crystals
as mass detectors in liquid chromatography however,
limits of detection were poor and the crystals became 
saturated after a small number of injections. Clearly 
the routine use of such detectors in biopharmaceutical 
analysis is a long way off <17).
MASS SPECTROMETRIC DETECTORS.
Over the past ten years a considerable research effort 
has been expended on the production of an LC-MS system.
GC-MS systems have been in use for many years now and
the interfacing of GC-MS was a logical step as the
eluent from a GC was in the gaseous phase and this fits 
the sample requirements for the MS. With LC the solutes 
are in the liquid phase and LC &  MS are not directly
compatible. Vapourisation of the HPLC eluent is 
necessary and different approaches to this problem have
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been adopted.
One of the first LC—MS systems produced incorporated a 
moving wire for collection of the solute (18). This was 
later replaced by a moving belt system (19). The 
disadvantages encountered include restricted flow rate 
(max lml/min) and eluents containing buffers or polar 
modifiers produce a drastic reduction in sensitivity. To 
extend the range of HPLC applications microbore columns 
are being used as these operate with very small amounts 
of eluent. Although different types of transport systems 
have been used it is generally agreed that microbore 
systems should be interfaced using techniques that do 
not use transport devices i.e. direct liquid injection 
systems.
SAMPLE PREPARATION.
The analysis of drugs in biological fluids by HPLC can 
often be troubled by interferences from endogenous 
compounds and several different approaches can be 
applied to tackle this problem. The solution may involve 
the use of a more selective detector, a change of the 
HPLC eluent or column packing material or even a 
chemical derivitasation in order to enhance the relative 
detector response of a drug. An alternative approach 
involves the modification of the sample preparation
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procedure such that the interfering compounds are 
eleminated before chromatography.
Protein precipitation using either an acid solution such 
as trichloroacelic acid or using solvent preciptation 
with miscible organic solvents such as methanol or 
acetonitrile can be employed. Liquid - liquid
extractions however have remained the most popular 
method of sample preparation for a number of years. 
Liquid-solid extraction either "on” or "off line" have 
recently become very popular.
On line solid extraction involves the use of column 
switching technology to selectively remove interfering 
biological material while holding the analyte of 
interest on a pre column before it's application to the 
analytical column.
The Rheodyne 7000 six port switching valve is typical of 
those used for column switching applications. During 
this procedure the sample is injected directly onto a 
preconcentration column with an aqueous mobile phase 
flowing through it (Fig.l). This concentration column is 
typically packed with a packing material similar to that 
of the analytical column but of a larger particle size 
(for example 40u particle size for the concentration
22
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column and 5 or 10 u particle size for the
analytical column . Vhen serum components have been
removed to waste ,the valve is switched and the
eluent flows in the backflush mode through the
concentration column and on to the analytical 
column (Fig.2).
Such switching techniques allow for the direct 
injection of biological samples on to HPLC systems 
without the need for sample pretreatment. Column 
switching techniques can also be used for zone 
cutting. This is a technique where only the zone of 
interest is switched on to the analytical column 
(20). Much greater sensitivity is achieveable using 
this technique as interfering substances have been 
removed and greater detector sensitivity settings 
can be used.
Off line liquid solid sample preparations have also 
become very popular and the use of cartridges such 
as sep pack or bond elute for sample pretreatment 
to remove interfering substances from biological 
material is becoming widespread.
Small columns similar to syringe barrels (sep 
pack) or to micro filters (bond elute) filled with 
column packing material ( C8 ,C18 and CN are
25
most commonly reported in the litrature ) are firstly 
conditioned by washing with methanol followed by a wash 
with aqueous solution. The aqueous samples are then 
applied to the column followed by a number of washes 
with an aqueous solution to remove interfering 
substances.The bound analyte is then removed with a 
suitable eluent which may be evaporated followed by 
reconstitution in a suitable fluid for application onto 
the column (21) .
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GAS CHROMATOGRAPHY <GC)
The utility of gas liquid chromatography in drug level 
analysis is attested to by the large number of drugs 
that can be assayed using this technique. There are two 
basic modes of gas chromatography, gas liquid 
chromatography and gas solid absorbtion. Absorbtion GC 
employed an absorbtive solid column packing material and 
is mainly applied to gases and highly volatile 
compounds, for example volatile anasthetics and ethanol. 
The gas solid chromatography of volatile compounds is 
usualy performed using head space analysis of biological 
samples without organic solvent extraction. However, the 
predominant GC mode is by partitioning gas liquid
chromatography. The liquid stationary phase consists of
silicone plastomers or long chain hydrocarbons with low 
vapour pressure. These materials are actually solid at 
room temprature and melt at tempratures around 100C. 
Seperation of components of a mixture occurs by
partitioning between the liquid stationary phase and the 
mobile gas phase. Retention in the column is a function 
of the physicochemical interactions of the compound and 
the liquid phase the temprature and the flow rate of the 
gas phase. Partitioning GC is performed either on 
columns packed with an inert microparticulate support 
material that is coated with the stationary liquid
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phase, or on capillary tubes coated with the liquid 
phase on their inside wall. These latter capillary GC 
columns are highly effecient since turbulence of the 
carrier gas is minimised. With a column length of in 
excess of 100m. capillary GC offers the greatest 
seperation potential at present. Packed columns on the 
other hand are quite versatile and are sufficient for 
most applications in drug level monitoring.
Biological samples contain large amounts of polar non 
volitile materials such as peptides, sugars and amino 
acids which have to be removed prior to analysis by GC 
in order to prevent column deterioration. Organic 
solvent extractions are the most commonly used sample 
purification procedures for GC.
Gas chromatography is one of the most versatile 
techniques available to the analyst. The technique is 
finding it's way into an increasing number of 
industries, and is widening it's application within many 
of those industries. Gas chromatographs now range from 
sophisticated process control instruments costing tens 
of thousands of pounds, to the simple gas chromatographs 
used for teaching purposes. The spread of gas 
chromatography has been matched by changes in both 
instrumentation and peripherals. The main areas where
advances have been made include gas supplies injection 
systems, columns, ovens, detectors and data handling 
systems (24).
GAS SUPPLIES
Perhaps the most basic of requirements for gas 
chromatography are gases. A few years ago the gases were 
usually industrial grade and were supplied by cylinders 
standing alongside the instrument. Very often the gas 
streams required cleaning and purifying before being 
piped to the instruments. Today gas suppliers recognise 
the needs of chromatographers and can supply high grade 
gases requiring no further purificiation for 
chromatography (it is advisible however always to clean 
gases required for electron capture detectors).
Automatic cylinder changeover valves are now often 
fitted to cylinders remote from the laboratory this 
avoids sudden loss of carrier gas flow when cylinders 
are empty.
An interesting new development in gas supply systems is 
the "liquid cylinder " supplied by some companies. 
These cylinders combine high gas capacity with low 
volume, and would appear to be ideal for establishments 
running a number of chromatographs.
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It is now possible to run gas chromatographs without the 
use of any cylinder gases. In this case the gases are 
obtained from laboratory scale gas generators. Hydrogen 
generators for flame ionisation detector gas 
chromatographs have been available for some years. These 
operate by electryolysing water, and produce very high 
quality gas. A number of manufacturers, produce 
instruments specifically suitable for chromatography 
use. Air can be obtained from a simple compressor, but 
varying concentrations of impurities lead to detector 
instability, or baseline drift. Air purifier units, can 
overcome these difficulties by remoiving all impurities 
from the compressed air supply.
INJECTORS
The primary purpose of a chromatograph injection system 
is to place a homogeneous bolus of sample, in the vapour 
phase, at the start of the column. Whilst this a 
relatively simple matter when using liquid samples and 
packed columns, both gas analysis and capillary columns 
present problems of scale. Large volumes of sample are 
required for gas analysis, and it is often difficult to 
reproducibly inject these volumes manually. Specially 
designed gas sampling valves are available from most gas 
chromatograph manufacturers. These ensure that a 
reproducible volume of sample is injected provided both
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temperature and pressure are constant; this is 
relatively easy to arrange.
The analysis of very low concentrations of gases or 
pollutants requires the use of sample volumes of the 
order of several tens of litres. These volumes are far 
too large for commercial chromatographs. Adsorption 
techniques are often used for these analyses. Gas is 
drawn through tubes filled with an adsorbent such as 
charcoal or porous polymer beads. The compounds of 
interest will adsorb on the material in the tubes. The 
analytes can then be washed into a small volume of 
solvent, or flash evaporated onto the chromatograph. 
Unfortunately the latter technique, whilst more rapid 
will cause some differentiation because of the time lag 
required to heat the relatively large mass of adsorbent 
and sample tube.
Small sample volumes are generally required for 
capillary chromatography. Sample splitters are often 
used to route a proportion of the injected sample to 
atmosphere. Some sample differentiation by molecular 
weight is inevitable. Splitless and on-column injection 
techniques are also available.
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COLUMN'S
Column tehcnology has changed greatly in the past few 
years. Packed columns in glass or metal are still widely 
used for routine analyses. In general there have been 
few major imporvements in support or stationary phase 
materials during the last few years. On the other hand 
high resolution gas chromatography has become a much 
more routine technique. PLOT columns (porous layer open 
tube) are now available for gas analysis applicaians. 
The major advantage of small bore columns is that they 
provide high resolution from a relatively short 
analysis. This allows either more intensive instrument 
use, or more detailed analysis.
OVENS
Column ovens have also changed greatly. The replacement 
of the early linear proportional temperature controllers 
with logic and later microprocessor technology allowed 
very close control of oven temperature both in 
isothermal operation and during temperature programming. 
Microprocessors also facilitate the use of multiple ramp 
rates, a technique that can greatly speed up complete 
analyses.
The thermal mass of chromatography ovens is a very 
important factor. A high thermal mass tends to produce a
34
stable temperature environment within the oven. 
Unfortunately high thermal mass also reduces the maximum 
ramp rate of the oven, and prolongs the cool-down time. 
Very low thermal mass ovens have fast ramp and cool 
rates but tend to have poor isothermal temperature 
stability.
High power heaters are needed to achieve the fast ramp 
rates required; these are cycled on and off by the 
digital circuitry to maintain either a constant 
temperature, or one that is changing at a constant rate. 
Unfortunately stable isothermal operation normally 
requires very small amounts of additional head to 
maintain the set temperature. As it is very difficult to 
obtain a small amount of heat from a high power heater 
there is inevitably some temperature cycling within the 
oven. The effects of this can be minimised by using a 
large fan to circulate air rapidly around the oven, and 
a dump system to dispose of surplus heat. Unfortunately 
the energy of the fan also enters into the oven 
performance equation. Most gas chromatograph ovens are 
therefore a compromise between all of the factors and it 
is a tribute to the designers that most gas 
chromatograph ovens work extremely well with nearly all 
column configurations.
35
Advances in electronics will doubtless lead to greater 
refinement with respect to both uniformity and stability 
of temperature, and it may well be that future 
generations of gas chromatographs will have different 
oven software/hardware configurations for different 
column types and arrangements.
One interesting technique this is becoming increasingly 
important is multi-dimensional chromatography. This uses 
multiple columns in two or more ovens and is especially 
useful for complex mixture analysis. Many instruments 
now allow the storage, and instant recall of a 
number of specific methods.
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DETECTORS
Detectors are probably the components in which there has 
been most development in recent years. Research appears 
to be concentrated on two major areas; sensitivity and 
selectivity. Sensitivity has been enhanced both by 
careful design of the detector hardware, and better 
electronics in both amplifiers and power supplies. The 
advent of capillary chromatography has made great 
demands on detector technology, and the various detector 
manufacturers have not been slow to respond. Detector 
and amplifier response times have fallen significantly, 
and a new generation of thermal conductivity detectors 
have been developed.
Detector selectivity is becoming more important as 
resolution increases. The correct choice of detector can 
help to isolate specific compounds of interest from the 
general clutter of complex matrix. A new " turntable *’ 
detector called the thermionic ionisation detector has 
recently been developed and this is a variant of the 
catalytic nitrogen phosphorous detector in which the 
catalyst, it's temperature, and it's gas phase 
environment can be changed. The effect of these changes 
is to enhance response to certain goups of compounds, 
while supressing the response to others. This is 
potentially one of the most exciting detectors now
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available. Especially interesting is the fact that in
halogen mode it becomes sensitive at the point where the
electron capture detector becomes non-liner.
Virtually any physical or chemical property of a 
compound or group of compounds can be used as the basis 
of a chromatographic detector. One interesting 
development is the sorbtion detector system being 
developed by Dr. Brian Buffham and colleagues at
Loughborough University. The detector responds initially 
to the adsorption of the sample at the head of the 
column by producing a negative peak whose area is
relative to the volume of the sample. The desorption of 
each individual component from the column is then 
recorded as a positive peak in the usual way. Column and 
oven defects cause predictable baseline perturbations. 
The area of the negative peak should equal the sum of 
the areas of the positive peaks. This detector however 
is still in the experimental stage.
Gas chromatography is a mature, well established 
technique for biopharmaceutical analysis (22). In the 
search for positive peak identifications in GC, 
instrument manufacturers have given attention to fourier 
transformed infrared spectrometry (FTIR) as an 
alternative to the now well established GCMS systems.
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Gas chromatograms have recently been combined with 
matrix isolation sprectroscopy (23) . Matrix isolation
is a well established technique of trapping ions, 
molecules or free radicles in a crystilline cage at 
tempratures near to absolute zero, basically to permit 
improved spectral resolution by the lack of 
intramolecular interaction and the absence of molecular 
rotation.
DATA HANDLING SYSTEMS
Vith the development of storage devices such as the 
Winchester disc-drive, the range of applications of 
computer systems has increased so that information 
storage and retrieval are now as important as numerical 
computation. With the advent of knowledge based systems 
computing has brought analytical chemistry to a stage 
where method development and data interpretation can now 
be handled by the instrumentation thus assisting the 
chemist in ways previously unforseen.
The most common form of knowledge based system is the 
expert system (25) which contains encoded expert 
knowledge and is capable of exploiting this knowledge 
for problem solving purposes One of the earliest 
implementations of an expert system designed to solve a 
chemical problem was the Dendral system, developed at 
Stanford University (26). This system uses data from
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mass specrometry to predict the structure of target 
molecules by using rules about possible structures and 
fragmentation processes in the spectrometer. These rules 
have been obtained from two main sources. They have 
either been supplied by an expert, or been derived by an 
associated program which analyses the mass spectra data 
produced from a particular class of compounds to suggest 
probable fragmentation rules <27).
An expert system is a knowledge based system and may
consist of one or more programs. It is characterised by
three essential features
<1> a knowledge base containing modules of organised 
knowledge derived from an expert's skill.
<2> an inference engine that uses the knowledge from 
the knowledge base to supply intelligent advice or to 
assist with decision making on a specialised topic.
<3) an explanation facility that can be invoked to
explain the line of reasoning which has been followed to 
arrive at the advice given.
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COMPETATIVE PROTEIN BINDING ASSAYS
The saturable, high affinity binding of a drug to 
proteins represents the basis for competative binding 
assays.The nature of the protein can be used as a 
criterion for classifying these assays into 
immunoassays, which employ drug-specific antibodies and 
account for the major proportion of protein binding 
assays,and into assays utilising other proteins, for 
example, drug target enzymes, receptors, and carrier 
proteins. Immunoassays are further subdivided according 
to the analytical technique by which the fraction of
free and protein bound drug is measured; 
radioimmunoassay, enzyme immunoassay,flourescence
immunoassay etc. (1).
The major determinant of assay sensitivity and 
specificity is the nature of the 1igand-protein binding 
interaction,The affinity, or dissociation constant, 
limits the assay sensitivity.Extraction and seperation 
of the drug from non-specific serum protein binding may
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be necessary to achieve maximum assay sensitivity. 
Furthermore, the cross-affinity of the binding protein 
or other
compounds in the sample determins assay specificity 
for a drug. Many of the proteins selected for 
competitive binding assays are highly specific; yet drug 
metabolites and endogenous substrate analogs may be 
chemically very similar to the drug of interest and can 
interfere with the drug-protein binding process. It is 
therefore mandatory to carefully test for assay 
interferences by drug analogs which may be present at 
much higher concentrations than is the active parent 
drug and a cross-affinity of the protein to a drug 
metabolite of only 1% may cause significant assay 
interference.
RADI0IMMUNOASSAY
Radioimmunoassay (RIA) procedures are widely used for 
drug analysis in biological samples. The ligand S* is a
radioactively labeled tracer drug which binds to a drug- 
specific antibody as the protein. The nature of the 
antibody is responsible to a large extent for the 
quality of the RIA method, and antibody production 
therefore represents an important factor in the assay 
development. Drugs of low molecular weight (<1000) are 
normally inactive as antigens and do not produce 
antibodies. However, when coupled to a suitable protein
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via a chemical spacer bridge, drugs act as 
immunologically active haptens. The antibodies raised 
against a drug hapten-protein conjugate also recognise 
the unbound drug; good antibodies have affinity 
constants of >10 9/M toward the drug hapten.
ENZYME IMMUNOASSAY
Immunoassays involving enzyme-labeled antigens, haptens, 
or antibodies have been recently developed for a large 
number of macromolecules and small molecular weight 
substances serving as haptens. Enzyme immunoassays
(EIAs) are increasingly used in clinical laboratories 
for diagnositc tests and for therapeutic drug level 
monitoring. The advantageous features of the EIA include 
speed, simplicity, ready automation, and versatility, 
which render it suitable for routine clinical 
applications and rapid drug screening. Initial lack of 
sensitivity of the EIA, relative to the RIA , has been
largley overcome; for example, the EIA assay for
progesterone is sensitive to 15 pg/sample, using B- 
galac-tosidase as the enzyme label and a heterogeneous
EIA <28).
Thus the sensitivity and specificity of the EIA are
comparable to those of the RIA, while the EIA offers
advantages over the RIA in avoiding radioactive tracers
and in speed of analysis. Many articles in the litrature
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include comparison studies performed with the EIA, RIA, 
and specific physiochemical assays. The results indicate 
that the EIA and RIA are usually equivalent and specific 
for the test drug. However, the enzyme label introduces 
additional potential assay interferences by several 
mechanisms, including differential binding of free drug 
and enzyme label to the antibody, presence of enzyme 
inhibitors, and presence of enzyme activity in the test 
sample. These factors have to be eliminated or minimized 
for clinically useful EIA methods.
FLUORESCENCE IMMUNOASSAY
Fluorescence immunoassays are based on changes in the
fluorescent properties of fluoresceine caused by binding 
to a macromolecule; either fluorescence quenching or 
fluorescence polarization induction is measured, the
latter requiring a specialized fluorimeter.
Fluorescence immunoassays are rather sensitive; the
major disadvantage may be the potential for assay 
interference by nonspecific fluorescence quenching or 
background fluorescence by other compounds in the 
biological sample.
MONOCLONAL ANTIBODIES IN IMMUNOASSAYS
The field of drug immunoassay has greatly benefited from 
the production of monoclonal antibodies (29). These 
antibodies are obtained by harvesting spleen cells
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instead of serum from the immunized animal and then 
fusing these cells with myueloma cells. The generated 
hybrid cells retain the ability to produce antibodies 
and can be grown indefinitely without the growth 
limitations of differentiated cells.
POLAROGRAPHY
Polarography is based on microelectrolysis, with the 
generated current proportional to the drug 
concentration. The general term ” voltammetry ” is used 
for all current-voltage recording methods with 
microelectrodes, while polarography is normally 
performed with the dropping mercury electrode and the 
saturated calomel electrode as the auxiliary electrode. 
The drug potentials are usually given relative to the 
saturated calomel electrode. Dissolved oxygen is reduced 
to H202 at - 0. IV and therefore has to be removed from
the sample before polarographic analysis of many drugs. 
This can be achieved by bubbling nitrogen through the 
sample. The sensitivity of regular polarography can be 
as good as mMolar to uMolar for suitable samples, which 
is sufficient for some drugs at therapeutic serum 
levels. A more sensitive technique is pulse polarography 
<30). The main advantages of using differential-pulse 
instead of d.c. polarography for trace drug analysis are
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increased detection limits and more convenient 
measurement.
The most favourable comopounds for determination by 
differential-pulse polarography are those containing a 
nitro group <31). This group is reduced at small 
negative potentials and the reduction usually involves 
at least four electrons. Further, some nitro compounds 
are adsorbed quite strongly on mercury and as this 
results in a concentration process between pulses it 
increased the differential-pulse signal and improves 
determinations made directly in plasma samples.
It should be noted that some progress has been made in 
using cathodic stripping voltammetry to determin drugs, 
such as thioamines, that form insuluble salts with 
mercury<II), <32). Compounds particularly amenable to 
oxidation at carbon are phenols and amines. Particularly 
successful and important is the determination of
catecholamines. Structurally related to these is 
morphine, which is determined specifically in forensic 
applications. The paper by Peterson <33) shows the 
complementary use of spectrophotometric and voltammetric 
detectors.
Electrochemical sensors are particularly suited to 
invivo work. Ion-selective electrodes have been applied 
increasingly in this field as have voltammetric oxygen
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sensors. A recent application of a voltammetric sensor
is that for the determination of catecholamines in situ,
based on a graphite-loaded epoxy resin. <34).
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PART II
AN INVESTIGATION OF THE PHARMACOKINETIC INTERACTION 
BETWEEN XIPAMIDE AND TRIAMTERENE WHEN ADMINISTERED 
ALONE OR IN COMBINATION
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GENERAL SUMMARY
A double blind placebo controlled, 4-way crossover study 
was carried out to investigate the pharmacokinetics of 
single oral doses of xipamide (lOmg), triamterene (30mg) 
and Trirexan <10mg xipamide + 30mg triamterene) in a 
group of 12 healthy male volunteers . HPLC methodologies 
were developed for the measurement of both drugs in 
plasma. Plasma levels of xipamide and triamterene were 
measured using these validated HPLC methods . The 
individual plasma level data are presented as tables and 
the mean plasma levels are presented graphically.
The plasma level data obtained from these analyses were 
subjected to analysis using curve stripping (JANA) and 
the results from this procedure were further analysed 
using PC NONLIN in order to estimate half lives and 
area under the time/concentration curves, area under the 
curve was also measured using the trapezoidal method for 
the periods 0-4,0-6 and 0-24 hrs. This was done in order 
to acertain if there was any difference in the 
absorption rates of both compounds administered alone or 
in combination.
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ABOUT THE DRUGS UNDER INVESTIGATION
Xipamide is a diuretic derived from salicylic acid and 
has a structural resemblance to chlorihalidone. It's 
pharmacodynamic profile shows a diuretic efficacy is 
similar to that of frusemide (furosemide) at doses up 
to 40mg, but the onset and duration of action are 
comparable to those of hydrochlorothiazide. Xipamide has 
been studied mostly in the treatment of mild to moderate 
essential hypertension with few controlled studies of 
it's use in oedematous states. The efficacy of xipamide 
20 to 40mg once daily in patients with mild to moderate 
hypertension is comparable to that of bendrofluazide 
5mg. bumetanide lmg. or hydrochlorothiazide 50mg. when 
used alone in newly treated or previously treated 
patients. The addition of xipamide 20 to 40mg. daily to 
regimens containing B-blockers,adrenergic neuron- 
blocking drugs and/or methyldopa has resulted in a 
further reduction in blood pressure. A few studies in 
odemalous states suggest that xipamide 40 to 80 mg. is 
comparable in efficacy to equal doses of frusemide, and 
that the side effects of hypokalaemia, hyperuricaemia 
and increased blood glucose in diabetics or latent 
diabetics are similar to those of other diuretics. Thus, 
xipamide is a suitable alternative to other diuretics in 
the treatment of mild to moderate hypertension and 
combines the efficacy of frusemide with a less abrupt 
action in the treatment of oedema. Although structurally 
related to chlorthalidone xipamide is not a thiazide.
Following oral administration of xipamide 20mg to 14 
healthy vonunteers, the drug appeared to be completely 
absorbed, with maximum plasma concentrations of about 
3mg/L occurring within 1 hour (knauf and Mutschler,
1984). In an earlier study using labelled xipamide, peak 
plasma radio-activity representing 13% of the dose per 
litre occurred 0.75 to 2 hours after oral administration 
of 42mg to 3 healthy volunteers (Hempelmann and Dieker, 
1977).
A comparison of the area under the plasma concentration- 
time curve (AUC) after intravenous and oral 
administration of xipamide 20 mg to healthy subjects 
indicated an absolute bioavilablity of 73%. The volume 
of distribution of xipamide as calculated from the total 
plasma clearance and elimination half-life was 21L 
(Knauf and Mutschler, 1984).
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XIPAMIDE
^ OOS\ ^ V
CHLORTHALIDONE
FRUSEMIDE
Triameterene is a mild diuretic which appears to act 
mainly on the distal renal tubules. It produces a
diuresis in about 2 to 4 hours, reaching a maximum 
effect in about 6 hours. The full effect may be delayed 
until after several days of treatment.
Triamterene is incompletely but fairly rapidly absorbed 
from the gastro-intestinal tract. It has been estimated 
to have a plasma half-life of about 2 hours. It is 
extensively metabolised and is mainly excreted in the 
urine in the form of metabolites with some unchanged 
triamterene; variable amounts are also excreted in the 
bile. Animal studies have indicated that triamterene
crosses the placental barrier and is excreted in milk. 
Following administration of triamterene 100 or 200 mg by 
mouth to 7 healthy subjects and intravenous 
administration to 2, rapid and extensive metabolism 
occured, the metabolite 2,4,7-trimino-6-p-
hydroxyphenylpteridine being found in the plasma as soon 
as 30 minutes after a dose and at a concentration of up 
to 12 times that of the parent drug, and in the urine at 
1.5 hours (again at a much higher concentration than the 
parent drug). Excretion also occurred in the bile after 
either oral or intravenous administration, with faecal
excretion being the primary route in 1 subject.
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TRIAMTERENE
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XIPAMIDE METHODOLOGY
PLASMA XIPAMIDE ASSAY
ReaRents :
- Methanol. H.P.L.C. Grade.
- Nanopure Water.
- Disodium Hydrogen Orthophosphate, anhydrous. 
Grade.
- Orthophosphoric acid (conc,) Analar Grade.
- Helium Gas.
- Internal Standard Chlorothalidone.
- Sodium Bicarbonate. Analar Grade.
Ethyl Acetate Analar Grade.
Instruments :
- High pressure pump : M6000 A Waters.
- Automatic sample injector : Waters WISP 710B
- Column uBondapak : C18 <25cm x 4.6mm).
- Pre-Column uBondapak : C18 Guard Column.
- U.V. Detector : Spectra Physics PU8480 XR.
- Integrator : Shiraadzu C-R3A Chromatopac.
Analar
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Working Conditions :
Mobile Phase.
Methanol : Na HPO (0.05M pH 6.4)
35 : 63
- Flow Rate 1.4 ml/min.
Wavelength 240 nm.
- Chart Speed 2.5 cm/min.
- Retention Time Xipamide 10. 0 min.
Chlorotalidone 8.0 min.
- Sensitivity : 50 ng/ml of xipamide.
Standard Solutions :
Xipamide stock solution : 1.0 mg/ml <in Methanol).
Xipamide working stock : 100 ug/ml (1 ml stock + 9 ml
methanol/water (50:50))
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Preparation of Spiked Plasma Standards
9.5 ml of fluoride oxalate plasma was pipetted
labelled 20ml glass vials : Standards were spiked
follows, the volume adj usted with <50
methanol/water.
Concentration in 
Plasma ng/ml
Xipamide 
100 ug/ml
MEOH/H 
50: 50
50 5 ul 495 ul
100 10 ul 490 ul
250 25 ul 475 ul
500 50 ul 450 ul
1000 100 ul 400 ul
2500 250 ul 250 ul
5000 500 ul 0 ul
The glass vials were vortexed well.
op
Internal Standard
A working solution of 7.5 ug/ml was prepared in methanol 
from a stock solution of 100 ug/ml.
Assay Procedure
Plasma xipamide assay was carried out as outlined below. 
The method used was a modification of one previously 
developed at this laboratory. The extraction procedure
60
was based on that used at Whickham laboratories (1). 
Briefly .after the addition of sodium bicarbonate , 
Xipamide is extracted from plasma with ethyl acetate. 
After evaporation the solvent the residue is 
reconstituted in methanol and analysed by reverse phase 
HPLC.
Chromatography was carried out on a uBondapak C18 column 
with UV detection at 240 nm.
■ , v-1 ^
All standards and QC samples were assayed in duplicate 
and the mean values reported. Likewise, 10% of plasma 
samples were assayed in duplicate and the mean values 
reported.
1. Pipette 1.0 ml of plasma (spiked or unknown) into 
culture tube.
2. Add 50 ul of internal std. solution.
3. Add 100 mg of sodium bicarbonate and 4.0 ml of ethyl 
acetate to each tube.
4. Vortex for 30 seconds.
5. Mix on a rotary mixer for 15 minutes.
6. Centrifuge for 15 minutes at 4000 rpm.
7. Remove supernatant and dry under a nitrogen stream at
o
60 C.
8. Reconstitute the residue in 200 ul of methanol
9. Inject 10-30 ul supernatant onto HPLC system. 
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CALIBRATION DATA
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CALIBRATION DATA
50
100
250
500
1000
2500
5000
QC 200 
QC 600 
QC 1200 
QC 4000
Xipamide Added
ng/ml
ASSAY No. 1
Xipamide Found 
ng/ml
56. 7 
103. 8 
227. 5 
482. 9 
941. 5 
2500.8
5096.5
197. 4 
589. 6
1164.6 
4252.0
% Difference
+ 13.4 
+ 3. 8
- 9.0
- 3.4
- 5.9 
0. 0
+ 1.9
- 1.3
- 1.7
- 3.0
+ 6.3
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.pamic
ng/i
50
100
250
500
1000
2500
5000
200
600
1200
4000
CALIBRATION DATA
Added
ASSAY No. 2
Xipamide Found 
ng/ml
52. 9 
98. 9 
239. 1 
493. 3 
1000.3
2580.0
4940.0
205. 6 
586. 1 
1211.2
4212.1
% Difference
+  5.8
-  1 . 1
- 4 . 4
- 1.3 
0. 0
+  3.2
- 1.2
+ 2.8 
-  2.3
+  0 .9
+  5.3
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CALIBRATION DATA
Xipamide Added 
ng/ml
50
100
250
500
1000
2500
5000
QC 200 
QC 600 
QC 1200 
QC 4000
ASSAY No. 3
Xipamide Found 
ng/ml
*
108. 3 
241. 4 
503. 6 
951. 7
2443.8
5108.3
208. 1 
621. 0
1189.2
4192.4
% Difference
+ 8.3
- 3.4
+  0 .7
- 4.8
-  2.2 
+ 2.2
+ 4.1
+ 3.5
-  0.9
+ 4.8
* Insufficient sample for analysis.
CALIBRATION DATA
ASSAY No. 4
50
100
250
500
1000
2500
5000
QC 200 
QC 600 
QC 1200 
QC 4000
Xipamide Added
ng/ml
Xipamide Found 
ng/ml
46. 9 
111. 4 
250. 9 
488. 5 
986. 9
2504.0 
5013.4
200 . 2 
511. 8 
1149.9
4145.1
% Difference
+ 6.2 
+  11.4 
+  0 .4
-  2 .3
-  1.3
+ 0.2 
+  0.3
+ 0.1
-  14.7
-  4 .2
+  3 .6
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CALIBRATION DATA
50
100
250
500
1000
2500
5000
QC 200 
QC 600 
QC 1200 
QC 4000
Xipamide Added
ng/ml
ASSAY No. 5
Xipamide Found 
ng/ml
51. 9 
98. 5 
250. 3 
492. 7 
983. 8 
2493.4 
5030.0
199. 2 
579. 9 
1136.3 
3978.7
% Difference
+ 3.8
- 1.5 
+ 0.1
- 1.5
-  1 . 6
- 0.3 
+ 0.6
- 0.4
- 3.4
- 5.3
- 0.5
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50
100
250
500
1000
2500
5000
200
600
1200
4000
CALIBRATION DATA
Added
ASSAY No. 6
Xipamide Found 
ng/ml
55. 3 
106. 0 
230. 5 
483. 5 
874.8
2508.3
5169.3
215. 7 
667. 0 
1351. 8 
4490.6
% Difference
+ 10 . 6 
+ 6.0 
7.8 
3.3 
- 12. 5
+ 0.3
+ 3.4
+ 7.9
+ 11.2 
+ 12. 7
+ 12. 3
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50
100
250
500
1000
2500
5000
200
600
1200
4000
CALIBRATION DATA
Added
ASSAY No. 7
Xipamide Found 
ng/ml
55. 9 
113. 2 
252. 7 
486. 8 
840. 7
2490.9
5198.6
220. 5 
614. 4
1283.2
4229.7
% Difference
+ 11.8 
+  13.2
+ 1.1 
2.6 
- 15.9
0 . 4  
+ 4 . 0
+ 10.3
+ 2.4
+ 6.9
+ 5.7
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PLASMA XIPAMIDE LEVELS
70
PLASMA XIPAMIDE CONCENTRATION
TIME SUBJECT 1 2
PRE DOSE ND ND
0.5 hrs. 228 1320
1.0 hrs. 388 1102
1.5 hrs. 516 818
2.0 hrs. 564 644
3.0 hrs. 1047 456
4.0 hrs, 742 353
6.0 hrs. 446 207
8,0 hrs. 338 147
10.0 hrs. 262 117
12.0 hrs. 196 77
18.0 hrs. 121 ND
24.0 hrs. 75 ND
<ng/ml) POST DOSING VITH XIPAMIDE
3 4 5 6
ND ND ND ND
335 1010 1570 1115
1316 620 1204 1074
926 439 862 777
720 316 643 665
461 198 423 448
340 115 304 364
175 68 144 203
141 ND 123 154
117 ND 114 127
72 ND 79 96
ND ND ND 48
45 ND ND ND
PLASMA XIPAMIDE CONCENTRATION (ng/ml)
TIME SUBJECT 7 8
PRE DOSE ND ND
0.5 hrs. 352 275
1.0 hrs. 810 1608
1.5 hrs. 891 1315
2. 0 hrs. 909 1240
3. 0 hrs. 787 951
4. 0 hrs. 723 719
6. 0 hrs. 518 449
8.0 hrs. 412 349
10.0 hrs. 347 245
12.0 hrs. 322 207
18.0 hrs. 171 118
24.0 hrs. 101 ND
POST DOSING WITH XIPAMIDE
9 10 11
ND ND ND
747 108 1464
1279 299 1248
991 933 1069
867 818 904
528 583 684
427 461 488
274 271 304
223 227 206
159 185 163
139 129 112
82 50 68
56 ND ND
ND
283
908
1098
994
714
500
350
279
189
136
79
ND
12
PLASMA XIPAMIDE CONCENTRATION <ng/ml) POST DOSING WITH TRIREXAN
TIME SUBJECT 1 2 3 4 5 6
PRE DOSE ND ND ND ND ND ND
0. 5 hrs. 96 1334 919 449 818 823
1.0 hrs. 1202 1232 1329 409 1042 1138
1.5 hrs. 1208 929 1021 506 1279 782
2.0 hrs. 1201 647 760 568 662 591
3. 0 hrs. 882 471 511 291 486 429
4.0 hrs. 632 331 389 186 342 319
6.0 hrs. 348 221 228 89 214 211
8. 0 hrs. 281 185 189 57 148 120
10.0 hrs. 222 135 146 ND 111 94
12.0 hrs. 176 101 112 ND 84 46
18.0 hrs. 113 ND 60 ND ND ND
24.0 hrs. 72 ND ND ND ND ND
PLASMA XIPAMIDE CONCENTRATION (ng/ml) POST DOSING WITH TRIREXAN
TIME SUBJECT 7 8 9 10 11 12
PRE DOSE ND ND ND ND ND ND
0.5 hrs. 1414 1266 1020 ND 902 844
1.0 hrs, 1340 1424 1377 387 1275 891
1.5 hrs. 1078 1000 979 1037 1166 1051
2.0 hrs. 922 848 774 1042 914 1038
3.0 hrs. 641 628 571 620 602 570
4.0 hrs. 562 464 428 460 458 414
6.0 hrs. 411 311 286 281 270 314
8.0 hrs. 313 211 226 223 192 232
10.0 hrs. 241 174 177 158 152 188
12.0 hrs. 195 106 139 107 134 166
18. 0 hrs. 123 ND 81 97 ND 52
24. 0 hrs. ND ND ND ND ND ND
ASSAY VALIDATION
INTER ASSAY VALIDATION
Xipamide Concentration ng/ml
Added Found in 4 batches Mean
50 54. 4 54. 4 54. 5 50. 5 53.5
100 102. 2 100. 4 95. 8 90. 2 97. 2
250 227. 5 239. 0 241. 6 266. 6 243. 7
500 488. 9 488. 5 512. 2 498. 6 497. 1
1000 1026.4 995. 1 976. 3 1026.9 1006.2
2500 2513.1 2479.9 2464.2 2590.3 2511.9
5000 4990.9 5044.3 5058.4 4885.5 4994.8
CV Accuracy
SD % %
2. 0 3. 7 107. 0
5.4 5.5 97. 2
16. 5 6. 8 97. 5
11. 1 2.2 99. 4
24. 9 2.5 100. 6
56. 1 2.2 100.5
78. 4 1. 6 99. 9
I2JTRA ASSAY VALIDATION
Xipamide Concentration ng/ml
Added Found in 4 batches Mean
50 45. 9 57. 6 56. 1 53. 3 53. 2
100 93. 0 93. 1 103. 2 92. 6 95. 5
250 229. 9 247. 5 259. 2 262. 3 249. 7
500 515. 0 503. 3 510. 0 489. 5 504.5
1000 970. 8 975. 2 990. 5 983. 4 980. 0
2500 2469.3 2450.6 2474.9 2563.6 2489.6
5000 5083.2 5021,9 5037.9 4971.3 5028.6
CV Accuracy 
SD % %
5.2 9.8 106. 4
5.2 5.4 95. 5
14. 7 5.9 99. 9
11. 1 2,2 100. 9
8. 7 0.9 98. 0
50. 4 2.0 99. 6
46. 2 0.9 100. 6
TRIAKTEREH' m e t h o d o l o g y
PLASMA TRIAMTERENE ASSAY (HPLC)
- Methanol HPLC Grade.
- Dichloromethane HPLC Grade.
- Internal Standard Cianopramine.
- Diethyl ether HPLC Grade.
- Helium Gas.
- Isopropan-2-ol HPLC Grade.
- Nanopure Water.
Instruments :
- Spectra Physics Labnet H.P.L.C. System. 
(Integrator, pump, automatic injector).
- Fluorescence spectrometer LS-3. Perkin
- Column Spherisorb 3 Silica (15 x 4.6
- Pre column - Guard Pak Silica.
Elmer, 
cm) .
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Working; Conditions
- Mobile Phase :
70 : 30 *
Dichloro Methane : Methanol plus 0.1% Ammonia.
Flow Rate : 1.6 ml/min.
Fluorescence detector. Excitation 315 nm.
Emission Filter 420nm. 
Chart Speed. 0.5 cm/min.
Retention time Internal standard 1.9 minutes
Triamterene 2.9 minutes
Sensitivity. 5ng/ml triamterene.
^Following the use of a new replacement column, the 
mobile phase ratio was changed to 80 : 20 so as to
obtain closely related retention times.
Standard Solutions :
A stock solution <0.1mg/ml) was prepared in methanol.
A first working solution of 10 ug/ml was prepared as 
follows :
1 ml stock solution + 4 ml methanol + 5  ml nanopure 
water.
A further series of working standards were prepared in 
methanol/water (1: 1) from working solution (10 ug/ml) 
and these were 100, 200, 500, 1000, 2000, 4000, 6000
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50 -ul of each standard was taken and a 1 ml aliquot of 
plasma was spiked to give the following standard 
concentrations :
5, 10, 25, 50, 100, 200, 300 ng/ml.
Internal-Standards :
Cianopramine - 12.5 ug/ml in methanol/water <1:1).
Assay Procedure :
Plasma triamterene assay was carried out as outlined 
below.
Briefly, 1.0 ml plasma spiked with 50 ul internal 
standard solution <in methanol/water) was extracted with 
diethylether/isopropan-2-ol. After centrifugation, the 
organic layer <6 ml) was separated, dried and 
reconstituted with 200 ul methanol prior to injection 
onto the HPLC column.
Chromatography was carried out on a Spherisorb 3 silica 
column with fluorescence detection at 420 nm.
All standards and QC samples were assayed in duplicate 
and the mean values reported. Likewise, 10% of plasma 
samples were assayed in duplicate and the mean values 
reported.
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METHOD
1. Take 1 ml plasma. Spiked or unknown.
2. Add 50 ul of Internal standard.
3. Vortex.
4. Add 7 ml diethyl ether : Isopropan-2-ol (19:1).
5. Rotate for 15 minutes.
6. Centrifuge at 3000 rpm for 5 minutes.
7. Remove 6 ml of organic layer and evaporate under a
stream of Nitrogen at 35-37 C.
8. Reconstitute residue in 200 ul Methanol. Vortex 
well.
9. Inject 50 ul onto column.
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ASSAY VALIDATION
INTER ASSAY VALIDATION
Triamterene concentration ng/ml 
Added Found in 4 batches Mean
00
5 CO Co 4.2 4.6 4. 1 4^ DO
10 12. 1 12. 0 11. 4 12. 7 12. 1
25 25.9 24. 5 23. 4 24. 1 24. 5
50 49. 9 50. 7 49. 8 53. 9 51. 1
100 99. 1 96. 8 99. 7 91. 8 96. 9
200 204 . 8 206. 6 203. 3 193. 9 202. 1
300 296. 4 296. 3 297. 2 312. 3 300. 6
CV Accuracy
SD % %
o CO 7.9 84. 0
ino 4.2 121. 0
1. 1 4.4 98. 0
1.9 3.8 102. 2
3.6 3. 7 96. 9
5.7 2.8 101. 1
7.9 2.6 100. 2
INTEA ASSAY VALIDATION
Triamterene Concentration ng/ml
Added
5 4.6
Found in 
4.7
4 batches 
4.9 co
Mean 
4. 4
10 11.6 10.8 11.7 13. 7 12. 0
25 23. 6 23. 8 23. 5 24. 5 23. 4
50 48. 3 50. 9 49. 4 48. 9 49. 4
100 99. 6 101.2 104. 6 99. 0 101. 1
200 201. 5 198. 3 202. 0 211. 7 203. 4
300 301. 7 286. 9 295. 3 301. 7 296. 4
CV Accuracy
SD % %
0.7 15. 5 88. 0
1.2 10. 4 120. 0
0.6 2.6 93. 6
1. 1 2.3 98. 8
2.5 2.5 101. 1
5.8 2.8 101 . 7
7. 0 2. 4 98. 8
CALIBRATION DATA
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CALIBRATION DATA
ASSAY NO. 1
Triamterene Added Triamterene Found
(ng/ml) (ng/ml)
5 4.5
10 12.7
25 22.3
50 48.6
100 102.9
QC 15 
QC 40 
QC 75
13. 8 
41.3 
69. 9
% Difference
-10. 0 
+27. 0 
-10. 8 
-  2.8 
+ 2.9
- 8 . 0  
+ 3.3 
- 6 . 8
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Triamterene Added Triamterene Found
(ng/ml) Cng/ml) % Difference
CALIBRATION DATA
ASSAY NO. 2
5 4. 4 -12. 0
10 12. 2 +22. 0
25 23. 5 - 6 . 0
50 48. 4 - 3 . 2
100 102. 0 + 2.0
QC 15 12. 6 -16. 0
QC 40 35. 1 -12. 3
QC 75 75. 3 + 0.4
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CALIBRATION DATA
Triamterene Added 
(ng/ml>
5
10
25
50
100
QC 15 
QC 40
QC 75
ASSAY NO. 3
Triamterene Found 
< ng/ml)
5.4
9.9 
25. 2
49. 1 
85. 1
14, 4.
38. 4 
28. 3 
78. 7
74. 1
% Difference
+ 8.0 
— 1.0 
+ 0.8  
-  1.8  
-14. 9
- 4 . 0  
- 4 . 0  
-29. 3 
+ 4.9 
-  1.2
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CALIBRATION DATA
Triamterene Added 
< ng/ml>
5
10
25
50
100
QC 15
QC 40 
QC 75
ASSAY NO. 4
Triamterene Found 
(ng/ml)
5. 7
9. 8 
22. 6
50. 4 
104. 3
12. 5 
19. 4 
17. 0
39. 7 
44. 2
75. 6 
82. 0
% Difference
+ 14. 0 
- 2 . 0
- 9.6 
+ 0.8  
+ 4.3
-16. 7 
+29.3*
+ 13. 3
-  0 . 8  
+10. 5 
+  0 . 8  
+ 9.3
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Triamterene Added 
<ng/ml)
5
10
25
50
100
QC 15 
QC 40 
QC 75
CALIBRATION DATA
ASSAY N O . 5
Triamterene Found 
C ng/ml>
5.7
10. 7
21 . 6 
48. 0 
99. 9
% Difference
+ 14. 0 
+ 7.0 
-13. 6 
- 4 . 0  
- 0 . 1
15. 0 
37. 9 
76. 3
0
- 2 . 1  
+ 1.7
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CALIBRATION DATA
ASSAY NO. 6
Triamterene Added Triamterene Found
(ng/ml) (ng/ml) % Difference
5 5.4 + 8 , 0
10 10.2 + 2 . 0
25 23.5 - 6 . 0
50 49,0 - 2 . 0
100 97.6 - 2 . 4
QC 15 16.1 + 7 . 3
QC 40 41.2 + 3 . 0
33.6 -16,0*
QC 75 77.6 + 3 . 5
72.7 - 3 . 1
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CALIBRATION DATA
Triamterene Added 
(ng/ml)
5
10
25
50
100
QC 15 
QC 40 
QC 75
ASSAY N O . J
Triamterene Found 
(ng/ml)
5. 0 
1 1 . 6
22 . 2 
48. 1 
103. 9
14. 4
40. 8
76. 5
% Difference 
0
+ 16. 0 
- 11.2 
- 3 . 8  
+ 3.9
- 4 . 0  
+ 2.0 
+ 2.0
93
CALIBRATION DATA
ASSAY NO. 8
Triamterene Added Triamterene Found
(ng/ml) (ng/ml) % Difference
5 4.3 -14.0
10 13.1 +31.0
25 22.0 -12.0
50 51.3 + 2 . 6
100 100.4 + 0.4
QC 15 14.5 - 3 . 3
QC 40 39.5 - 1 . 3
QC 75 86.3 +15.1
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CALIBRATION DATA
ASSAY NO. 9
Triamterene Added Triamterene Found
(ng/ml) (ng/ml) % Difference
5 5.2 + 4 . 0
10 10.2 + 2 . 0
25 23.2 - 7 . 2
50 54. 0 + 8.0
100 94.5 - 5 . 5
QC 15 15.5 + 3 . 3
QC 40 40.5 + 1.3
QC 75 71. 0 - 5.3
77.7 + 3 . 6
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PLASMA TRIAMTERENE LEVELS
PLASMA TRIAMTERENE CONCENTRATION
TRIAMTERENE
TIME SUBJECT 1 2
PRE DOSE ND ND
0.5 hrs. 18 76
1.0 hrs. 23 56
1.5 hrs. 17 45
2 . 0 hrs. 20 33
3.0 hrs. 12 17
4.0 hrs. 7 9
6. 0 hrs. ND ND
8. 0 hrs. ND ND
10.0 hrs. ND ND
12.0 hrs. ND ND
18.0 hrs. ND ND
24.0 hrs. ND ND
POST DOSING
4
< ng/ml> 
3
ND
36
30
20
14
9
ND
ND
ND
ND
ND
ND
ND
ND
36
31
17
19
7
ND
ND
ND
ND
ND
ND
ND
VITH 
5
ND
73
83
68
64
45
30
12
ND
ND
ND
ND
ND
ND
47
53
35
28
16
9
5
ND
ND
ND
ND
ND
6
PLASMA TRIAMTERENE LEVELS <ng/ml)
TIME SUBJECT 7 8
PRE DOSE ND ND
0.5 hrs. 64 43
1.0 hrs. 43 52
1.5 hrs. 29 39
2.0 hrs. 22 29
3.0 hrs. 10 16
4.0 hrs. 5 11
6.0 hrs. ND ND
8.0 hrs. ND ND
10.0 hrs. ND ND
12.0 hrs. ND ND
18.0 hrs. ND ND
24.0 hrs. ND ND
POST DOSING WITH TRIAMTERENE
9 10 11
ND ND ND
36 42 27
30 30 53
39 24 52
28 20 43
13 18 19
9 5 10
ND ND ND
ND ND ND
ND ND ND
ND ND ND
ND ND ND
ND ND ND
12
ND
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43
28
26
14
8
6
ND
ND
ND
ND
ND
PLASMA TRIAMTERENE LEVELS (ng/ml)
TIME SUBJECT 1 2
PRE DOSE ND ND
0.5 hrs. ND 47
1.0 hrs. 39 43
1.5 hrs. 24 35
2.0 hrs. 22 29
3.0 hrs. 9 18
4.0 hrs. ND 12
6. 0 hrs. ND ND
8. 0 hrs. ND ND
10,0 hrs. ND ND
12.0 hrs. ND ND
18.0 hrs. ND ND
24.0 hrs. ND ND
POST DOSING WITH TRIREXAN
3 4 5
ND ND ND
5 5 20 70
42 11 101
34 21 75
22 16 56
13 11 38
8 9 24
ND 7 22
ND ND 11
ND ND ND
ND ND ND
ND ND ND
ND ND ND
6
ND
56
45
29
19
13
7
ND
ND
ND
6
ND
ND
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PLASMA TRIAMTERENE CONCENTRATION
TIME SUBJECT 7 8
PRE DOSE ND ND
0.5 hrs. 59 44
1.0 hrs. 39 32
1,5 hrs. 28 38
2.0 hrs. 21 32
3.0 hrs. 10 19
4.0 hrs. 5 11
6.0 hrs. ND ND
8.0 hrs. ND ND
10,0 hrs. ND ND
12.0 hrs. ND ND
18. 0 hrs. ND ND
24.0 hrs. ND ND
POST DOSING WITH TRIREXAN
9 10 11 12
ND ND ND ND
64 ND 97 79
56 26 63 39
34 50 55 28
23 26 31 22
11 15 16 11
5 11 12 10
ND 6 ND ND
ND ND ND ND
ND ND ND ND
ND ND ND ND
ND 6 ND ND
ND ND ND ND
PHARMACOKIJETIC DATA
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ANALYSIS
Fharmacokinetic Data analysis
Flasraa Xipamide levels measured over a 24 hour period 
post dosing with Xipamide alone and in a fixed 
combination as Trirexan were analysed using the JANA 
curve stripping prgram. The estimates of the
pharmacokinetic parameters thus obtained were then used 
in curve fitting analysis using an IBM-FC compatible 
version of NONLIN 84. Plasma triamterene levels post 
dosing with Triamterene and Trirexan were likewise 
analysed.
Xipamide
The mean AUC values after dosing with Xipamide and 
Trirexan were 5554 and 5255 ng.h/ml respectively, and 
the mean elimination half-life values were 3.82 and 3.14 
h. The mean observed Cmax values were 1222 and 1203 
ng/ml, and the mean observed Tmax values were 1.13 and
1.21 h. These mean values were not significantly 
different (p > 0.05).
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Tr iamt erene
The mean AUC values post dosing with Triamterene and 
Trirexan were 138 and 145 ng.h/ml respectively, and the 
mean elimination half-life values were 1.28 and 1.47 h. 
The mean observed Cmax values were 54 and 59 ng/ml, as
the mean observed Tmax values were 0.79 and 0.75 h. 
These mean values were not significantly different 
<p > 0. 05) .
There were no statistically significant differences 
between the pharmacokinetic parameters studied after 
administration of either formulation.
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THE JANA PROGRAM
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THE JANA COMPUTER PRIOGRAM FOR EXPONENTIAL STRIPPING OF 
PHARMACOKINETOC DATA
This program is used for the statistical analysis of 
pharmacokinetic data. The model used is the
polyexponential equation
Y = A,exp C -B, (t-L))
where Y is the response variable e.g. plasma drug 
concentration at time t following drug administration, m 
is the number of exponential terms with exponents B,and 
L is the lag time if one is required.
Anlysis of pharmacokinetic data generally involves a 
parameter estimation or curve fitting step which is 
frequently accomplished by a nonlinear least squares 
regression program e.g. PCNONLIN (1). However, 
nonlinear least squares programs require initial 
estimates of the parameters and the success of the least 
squares analysis depends on how good the initial 
estimates are . A number of graphical/numerical 
techniques have been described <2-7) for the provision 
of initial parameter estimates for polyexponential 
models . The most commonly used of these is curve 
stripping (8) . This method assumes that the terminal 
data points can be described by a single exponential 
term and its coefficient and exponent are estimated by 
fitting a straight line to these points on a 
semi-logarithmic plot. The value of this exponential 
term at all of the earlier times is estimated using 
these parameter estimates and subtracted from the 
original data to yield a set of so-called residuals. 
The terminal residuals are assumed to described by a
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single exponential term whose parameters are estimated 
by fitting a straight line to them on a semi-logarithmic 
plot. This procedure is repeated until the desired 
number of exponential terms have been accounted for and 
their parameters estimated. This method has been
automated for digital computers (9-11).
The curve stripping technique makes the assumption that 
the exponential terms do not significantly overlap one 
another and consequently their parameters may be 
estimated one term at a time. This assumption is 
approximately true if the ratios of the exponents are 
large i.e.
B1 >> B2 >> B3.............. >>Bm
However , violation of this assumption would be expected 
to yield biased parameter estimates (12-14).
JAITA is based on an approach to curve stripping which 
does not make any assumption regarding the ratios of the 
exponents. This technique iteratively corrects for 
overlap of the exponent terms (15-18).
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MODELLING, NONLINEAR REGRESSION AND PHARMACOKINETICS 
The value of mathematical models is well recognised in 
all of the sciences - physical , biological , behavioral 
and others .Models are often used in the quantitative 
analysis of all types of observations or data and with 
the power and availability of computers , mathematical 
models provide convenient and powerful ways of looking 
at data. Models can be used to help interpret data , to 
test hypotheses and to predict future results. Ve are 
concerned in pharmacokinetics with "fitting" models to 
data ; that is , finding a mathematical equation and a 
set of parameter values such that values predicted by 
the same model are in some sense "close” to the observed 
values.
The most commonly encountered of these models are linear 
models in which the dependent variable can be expressed 
as the sum of products of the independent variables and 
parameters. The simplest example being the equation of 
a line :-
Y = A + B*X
where Y is the dependent variable , X is the independent
variable , A is the intercept and B is the slope. Other
commonly used examples are polynomials such as : -
2 3
Y = A1 + A2*X + A3XX + A4*X
and multiple linear regression
Y = A1 + A2*X1 + A3*X2 + A4*X3
These examples are all "linear models" since the
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parameters appear only as coeffecients of the 
indepfndent variables.
In non linear models , at least one of the parameters 
appears as other than a coeffecient . A simple example 
is the decay curve
Y = YO*exp(-B*X>
This model can be linearised by taking the log of both 
sides but as written it is nonlinear. There are many 
models which cannot be made linear by transformation. 
One such model is the sum of two or more exponentials, 
such as
Y = Al*exp(-Bl*X> + A2*exp(-B2*X>.
These models are called nonlinear models or nonlinear 
regression models. All pharmacokinetic models derive 
from a set of basic differential equations. Given a 
model of the data and a set of data some criteria of 
best fit is needed and the most frequently used is the 
least squares method. In the least squares method the 
best estimates are those which minamise the sum of the 
squares of the deviations between the observed values 
and the values predicted by the model.
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XIPAMIDE 
PHARMACQKINETICS
110
EL IMIHATION HALF-LIFE AMD AUC VALUES 
2-3 EXPONENTIAL MODELS 
(using PC NONLIN Curve Fitting)
Drug:__ Xipamide/Trirexan
XIPAMIDE TRIREXAN
Subj .
r
Squared
El im. 
t-1/2 
h
AUC 
ng.h/ml
r
Squared
Elim.
t-1/2
h
AUC 
ng.h/ml
1 0. 810 3. 64 6920 0. 834 2. 83 6464
2 0. 994 3. 36 4645* 0. 998 4. 94 5115*
3 0. 964 1. 23 3588 - cd cd
4 - cd cd 0. 949 1. 61 1988
5 0. 998 4. 13 4565* 0. 931 1. 66 3830
6 0. 998 4. 12 4635* 0. 960 1. 86 3432
7 0. 976 2. 86 6402 0. 998 5. 91 7920*
8 - cd cd - cd cd
9 0. 953 2. 50 5151 - cd cd
10 - cd cd - cd cd
11 1. 000 5. 96 6551* 0. 978 2. 06 4839
12 0. 953 2. 69 5163 0. 953 2. 69 5184
Mean 3. 39 5291 2. 95 4847
Std. Dev. 1. 32 1106 1. 61 1830
N 9 9 8 8
cd = Parameter values cannot be determined with reasonable accurac
* = Parameter values (determined using 3 exponential model.
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• 112
Drug;: Xipamide
Subj. r Derived Parameters
Initial estimates of derived parameters
2-3 Exponential Terms (JANA Curve Stripping)
fo. Squared A1 A2 A3 B1 B2 B3
1 0. 782 1144 -1145 NA 0.1244 0.6422 NA
2 0. 999 669 1492 -2161 0.1808 1.0418 4. 999
3 0. 808 3078 -3080 NA 0.5740 1.5251 NA
4 0. 982 511 1579 -2090 0.3429 1.6476 4,1753
5 0. 999 392 2169 -2561 0.1359 0.9214 5.4899
6 0. 997 443 1517 -1959 0.1257 0.7878 3.6030
7 0. 951 1027 -1027 NA 0.0999 2.0930 NA
8 0. 857 621 3819 -4415 0.0924 0.5554 1.0884
9 0. 786 870 -870 NA 0.1323 5.1300 NA
10 0. 682 923 3895 -4818 0.1623 1.7980 1.4505
11 0. 999 315 1446 -1760 0.0878 0.4054 9.2251
12 0, 843 1098 -1099 NA 0.1629 3.2061 NA
NA = Nat applicable to 2 exponential model.
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Drug:_Xipamide
Subj. r Derived Parameters
Final estimates of derived parameters
2-3 Exponential Model (PCNONIN Curve Fitting)
ro. Squared Al A2 A3 B1 B2 B3
l 0. 810 1534 -1714 NA 0.1907 1.5259 NA
2 0. 994 724 1535 -2256 0.2064 0.9198 4.2510
3 0. 964 3050 -3070 NA 0.5658 1.7034 NA
4 - cd cd cd cd cd cd
5 0. 998 477 2082 -2559 0.1680 0.9510 5.5228
6 0. 998 636 2201 -2837 0.1682 1.1957 2.8802
7 0. 978 1610 -1599 NA 0.2421 6.4414 NA
8 - cd cd cd cd cd cd
9 0. 953 1541 -1577 NA 0.2773 3.8969 NA
10 - cd cd cd cd cd cd
11 1. 000 423 1356 -1779 0.1162 0.4339 8.3812
12 0. 953 1507 -1508 NA 0.2575 2.1900 NA
NA = Not applicable to 2 exponential model.
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Drug: Trirexan
Subj. r Derived Parameters
Initial estimates of derived' parameters
2-3 Exponential Terms (JANA curve stripping)
fo. Squared Al A2 A3 B1 B2 B3
1 0. 729 1648 -1650 NA 0.1489 1.9046 NA
2 0. 997 488 2545 -3032 0.1292 1.0224 3.0821
3 0. 973 425 3077 -3505 0.1091 0.8705 2.0627
4 0. 944 967 -967 NA 0.3788 1.8297 NA
5 0. 873 1160 -1160 NA 0.2396 3.4097 NA
6 0. 934 1097 -1097 NA 0.2650 4,1441 NA
7 0. 997 749 2474 -3224 0.1053 1.0722 2.9313
8 0. 991 852 2630 -3482 0.1692 1.0951 2.4205
9 0. 975 489 3123 -3612 0.1011 0.8682 1.8005
10 0. 700 185 1849 -2035 0.0408 0.4412 1.2705
11 0. 935 1304 -1304 NA 0.2152 3.1596 NA
12 0. 917 1078 -1078 NA 0.1717 4.0055 NA
NA = Not applicable to 2 exponential model
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Drug: Trirexan
Final estimates of derived parameters
2-3 Exponential Terms <PCNONLIN Curve Fitting)
>ubj . 
lo.
r
Squared A1 A2
Derived
A3
Parameters
B1 B2 B3
1 0. 834 2030 -2248 UFA 0.2450 1.2337 NA
2 0. 998 513 2549 -3064 0.1402 1.0471 3.1226
3 - cd cd cd cd cd cd
4 0. 949 1212 -1199 HA 0.4315 1.4616 NA
5 0. 931 2056 -2090 NA 0.4187 1.9321 NA
6 0. 960 1469 -1494 NA 0.3736 2.9930 NA
7 0. 998 800 2380 -3180 0.1173 1.0994 2.9714
8 - cd cd cd cd cd cd
9 - cd cd cd cd cd cd
10 - cd cd cd cd cd cd
11 0. 978 1922 -1942 NA 0.3363 2.2179 NA
12 0. 953 1516 -1508 NA 0.2575 2.1503 NA
116
Paired t-Test Result
Drugs : Xipamide and Trirexan.
Cmax T-max
ng/ml h
Mean
Xipamide 1222 1.13
Trirexan 1203 1.21
Std. Error 70 0.25
t-value Probability 0.792 0.746
N 12 12
HI in. t 1/2 AUC
h ng.h/rol
3.82 5554
3.14 5255
0.92 409
0.512 0.504
7 7
MEAN PLASMA XIPAMIDE LEVELS (N=12)
Drug:__Xipamide and Trlrexan
Time Xipamide Trirexan
ng/ml
Pre Dose 0
0.5 hr Post Dose 733
1 hr " ” 988
1.5 hr " ” 886
2 hr ” ” 774
3 hr '• ” 607
4 hr “ ” 461
6 hr ” ” 284
8 hr *' ” 217
10 hr ” ” 169
12 hr ” *’ 130
18 hr " *’ 61
24 hr ” " 23
For determination of mean value ND = 0 ng/ml.
ng/ml
0
824
1087
1003
831
559
415
265
198
150
114
44
6
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MEAN PLASMA XIPAMIDE LEVELS (ng/ml) POST DOSING WITH XIPAMIDE (•) AND TRIXEXAN (■) N = 12
1000
800
600
400
200
TIME/LVS
1
1
8
TRIAMTERENE 
PHARMACOKINETICS
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ELIMINATION HALF-LIFE AND AUC VALUES
2-3 EXPONENTIAL MODELS 
(using PC NONLIN Curve Fitting)
TRIAMTERENE TRIREXAN
>ubj •
r
Squared
t-1/2
Elim.
h
AUC 
ng.h/ml
r
Squared
t-1/2
Elim.
h
AUC
ng/h/m
1 0. 972 1. 35 72 - cd cd
2 0. 998 1. 15 161 0. 994 1. 41 132
3 0. 992 0. 98 71 0. 996 1. 14 118
4 0. 976 0. 90 70 0. 878 2. 72 89
5 0. 994 1. 81 298 0. 964 1. 56 288
6 0. 988 1. 31 132 0. 994 0. 98 109
7 - cd cd 0. 996 0. 90 104
8 0.988 1. 30 135 0. 966 1. 80 135
9 0. 956 1. 45 116 0. 998 0. 76 116
10 0. 978 1.41 102 0. 701 1. 82 129
11 0. 951 1. 21 154 0. 992 1. 01 185
12 0. 998 1. 60 170 * - cd cd
Mean 1. 32 135 1. 41 141
Std. Dev. 0. 26 65 0. 59 57. 8
N 11 11 10 10
Parameter values idetermined using 3 exponential model.
cd = Parameter values cannot be determined with reasonable accuracy.
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Druy: Triamterene
Subj. r Derived Parameters
Initial estimates of derived parameters
2-3 Exponential Terms (JANA curve stripping)
ro. Squared Al A2 A3 B1 B2 B3
l 0. 958 34. 8 -34. 8 NA 0.3783 2.3414 NA
2 0. 997 110.3 -110.3 NA 0.6222 6.2765 NA
3 0. 984 50. 4 l Ol o 4^ NA 0,5932 7.0478 NA
4 0. 975 59. 4 1 CJl © NA 0.6903 4.5719 NA
5 0. 992 129. 8 -129.8 NA 0.3833 2.6686 NA
6 0. 979 72. 5 -72. 5 NA 0.4723 3.9116 NA
7 0. 878 1326.9 -1326.9 NA 2.3809 2.7264 NA
8 0. 982 85. 1 -85. 1 NA 0.5277 2,6714 NA
9 0. 948 63. 5 -63. 5 NA 0.4864 3.0563 NA
10 0. 974 57. 1 -57. 1 NA 0.5351 6.9923 NA
11 0. 935 145. 6 -145.7 NA 0,6849 1.8309 NA
12 0, 996 44. 0 350. 9 -394.8 0.3577 3.3544 7.:
HA = Not applicable to 2 exponential model.
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Drug:_Triamterene
Subj. r Derived Parameters
Final estimates of derived parameters
2-3 Exponential Terms (PCNONLIN Curve Fitting)
Jo. Squared A1 A2 A3 B1 B2 B3
1 0. 972 51. 7 -51. 8 NA 0,5122 1.7788 NA
2 0. 988 106. 8 -106.9 NA 0.6053 6.9352 NA
3 0. 992 58. 9 -58. 5 NA 0.7104 4.7994 NA
4 0, 976 67. 8 -67. 9 NA 0.7699 3.8252 NA
5 0. 994 134. 8 -134.4 NA 0.3839 2.5126 NA
6 0. 988 82. 4 -82. 4 NA 0.5279 3.4177 NA
7 - cd cd cd cd cd cd
8 0. 988 89. 5 -89. 7 NA 0.5329 2.6809 NA
9 0. 956 69. 0 -68. 5 NA 0.4779 2.4242 NA
10 0. 978 52. 9 -52. 7 NA 0.4925 8.9543 NA
11 0. 951 152. 8 -155.5 NA 0.5742 1.3842 NA
12 — cd cd cd cd cd cd
cd = Parameter values cannot be determined with reasonable accuracy.
NA = Not applicable to 2 exponential model.
PruR:_Trirexan
SubJ. r Derived Parameters
Initial estimates of derived parameters
2-3 Exponential Terms (JANA curve stripping)
lb. Squared A1 A2 A3 B1 B2 B3
1 0. 601 118. 9 -119.0 NA 0.8938 1.8701 NA
2 0. 992 67. 8 -67. 8 NA 0.4349 4.3650 NA
3 0. 996 73. 7 -73. 7 NA 0.5650 9.8845 NA
4 0. 818 25. 7 -25. 7 NA 0.2353 1.6861 NA
5 0. 937 107.4 -107.4 NA 0.2930 3.1045 NA
6 0. 976 236. 6 -236.6 NA 1.2870 2.4604 NA
7 0. 960 81. 9 -81. 9 NA 0.6983 3.8568 NA
8 0. 964 55. 3 -55. 3 NA 0.3759 6.8367 NA
9 0. 995 116. 2 -116.2 NA 0.7897 4.1922 NA
10 0. 699 65. 2 -65. 3 NA 0.4354 1.2863 NA
11 0. 977 114. 4 -114.4 NA 0.5961 9.1615 NA
12 0, 685 14, 6 56. 6 -71. 3 0.0953 0.8719 3.2200
NA = Not applicable to 2 exponential model.
PruK: Trirexan
Subj. r Derived Parameters
Final estimates of derived parameters
2-3 Exponential Terms <PCNONLIN Curve Fitting)
To. Squared Al A2 A3 B1 B2 B3
1 - cd cd cd cd cd cd
2 0. 994 74. 7 -74. 7 NA 0.4908 3.6949 NA
3 0. 996 79. 3 -79. 3 NA 0.6063 6.1346 NA
4 0. 878 23. 3 -23. 5 NA 0.2546 9.1060 NA
5 0. 964 157. 5 -158.0 NA 0.4447 2.3735 NA
6 0. 994 88. 3 -88. 4 NA 0.7074 5.4445 NA
7 0. 996 89. 8 -89. 1 NA 0.7661 6.7459 NA
8 0. 996 54. 9 -54. 9 NA 0.3849 7.1201 NA
9 0. 998 146. 9 -146.9 NA 0.9093 3.2603 NA
10 0. 701 74. 6 -79. 8 NA 0.3800 1.1749 NA
11 0. 992 135. 5 -135.3 NA 0.6889 11.6576 NA
12 _ cd cd cd cd cd cd
cd = Parameter values cannot be determined with reasonable accuracy.
NA = Not applicable to 2 exponential model.
OBSERVED Cmax AND Tmax VALUES
riamterene and Trirexan
TRIAMTERENE TRIREXAN
Cmax Tmax Cmax Traax
Subj.No. ng/ml h ng/ml h
1 23 1. 00
• • ^  V*
39 oo
2 76 0. 50 47 0. 50
3 36 0. 50 55 0. 50
4 36 0. 50 21 1. 50
S 83 1. 00 101 1. 00
6 53 1. 00 56 0. 50
7 64 0. 50 59 0. 50
8 52 1. 00 44 0. 50
9 39 1. 50 64 0. 50
10 42 0. 50 50 1. 50
11 53 1. 00 97 0. 50
12 92 0. 50 79 0. 50
Mean 54 0. 79 59 0. 75
Std. Dev. 21 0. 33 23 0.40
N 12 12 12 12
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Paired t-Test Result
Drugs : Triamterene and Trirexan.
Cmax Tmax
ng/ml h
Mean
Triamterene 54 0.79
Trirexan 59 0.75
Std. Error 6 0.17
t-value Probability 0.605 0.803
U 12 12
El in. t 1/2 AUC
h ng.h/ml
1.28 
1. 47
0. 24 
0. 533 
9
138
145
9
0. 550 
9
MEAN PLASMA TRIAMTERENE LEVELS <N=12)
Drug : Triamterene and Trirexan.
Triamterene Trirexan
Time ng/ml ng/ml
Pre dose 0 0
0.5 hr. post dose 49 49
1.0 hr. 44 45
1.5 hr. 34 38
2.0 hr. 29 27
3.0 hr. 16 15
4.0 hr. 9 10
6. 0 hr. 2 3
8.0 hr. 0 1
10. 0 hr. 0 0
12.0 hr. 0 1
18.0 hr. 0 1
24.0 hr. 0 0
For the determination of mean values ND = 0 ng/ml.
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MEAN PLASMA TRIAMTERENE LEVELS POST DOSING WITH TRIAMTERENE ( ) AND TRIREXAN ( ) (N=12)
TIME/HRS
1
2
8
DETERMINATION OF THE AREA UNDER THE 
TIME/CONCENTRATION CURVE USING THE TRAPEZOIDAL METHOD
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Determinat ion of the area -under the curve (AUC) us ins 
the trapezoidal method
Plasma xipamide and triamterene levels after dosing 
with xipamide, triamterene and Trirexan were also used 
to determine AUC values by the trapezoidal method over 
the following periods : 0—4, 0-6 and 0-24 hours.
a) Xipamide
The mean xipamide AUC values post dosing with xipamide 
and Trirexan over 0-4 hour period were 2721 (range 1523- 
3840) and 2846 (1492-3595) ng. h/ml respectively ; those 
over the 0-6 hour period were 3467 (1706-5008) and 3527 
(1767-4503), and over the 0-24 hour period 5510 (1774- 
8751) and 5225 (1970-7540 ng.h/ml). Paired t-test 
analysis showed that the AUC values for each of these 
periods were not significantly different (p = 0.320,
0.645 and 0.310 respectively). The AUC values obtained 
for subject 4 were consistently low (approx. 2 
standard deviations or more from the mean) irrespective 
of the drug formulation.
Over the 0-24 hour period, the AUC ratio
(Trirexan/xipamide) ranged from 0.70 to 1.26 with a
mean value of 0.98 ; only 1 value was just outside
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the lower limit range (subject 8 : 0.69). The AUC ratio
was essentially the same over the 3 periods studied.
b) Triamterene
The mean triamterene AUC values post dosing with 
triamterene and Trirexan over 0-4 hour period were each 
106 ng.h/ml, and the AUC ranges were 60-220 and 54-215 
ng.h/ml respectively. Those over 0-6 hour period were 
117 and 118 ng.h/ml respectively and the corresponding 
ranges were 63-262 and 57-261 ng.h/ml : those over 0-24 
hour period were 119 and 128 ng. h/ml and the 
corresponding ranges were 63-274 and 57-305 ng,h/ml. 
Paired t-test analysis indicated that the AUC values 
for each of these periods were not significantly 
different (p = 0.950, 0.847 and 0.251).
The AUC ratio over 0-24 hour period
(Trirexan/triamterene) ranged from 0.54-1.66 with a 
mean value of 1.10. One subject (number 3) was above 
the upper limit (1.70).
The AUC values indicated that triamterene absorption 
was complete 4 hours following triamterene and Trirexan 
administration, except in 2 subjects (No 3, 10) where a
longer absorption process was apparent.
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AUC VALUES (Trapezoidal Method^ 
DRUG: XIPAMIDE
AUC ng. h/nil
Subj ect 
1 
2
3
4
5
6
7
8
9
10 
11 
12
Mean 
S. D. 
n
0-4 hr ■
2407
2736
2460
1523
2875
2612
2857
3840
2900
2096
3497
2854
2721
599
12
0-6 hr. 
3595 
3296 
2975 
1706 
3323 
3179 
4098 
5008 
3601 
2828 
4289 
3704
3467
821
12
0-24 hr. 
6976 
4339 
4440 
1774 
4257 
4616 
8751 
8181 
5855 
4739 
6187 
6008
5510
1908
12
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AUC VALUES (Trapezoidal Method) 
DRUG: TRIREXAN (XIPAMIDE) 
AUCng.h/ml
Subj ect 
1 
2
3
4
5
6
7
8
9
10 
11 
12
0-4 hr. 
3352 
2869 
2910 
1492 
2723 
2403 
3530 
3341 
3054 
2344 
3188 
2949
0-6 hr. 
4332 
3421 
3527 
1767 
3279 
2933 
4503 
4116 
3768 
3085 
3916 
3677
0-24 hr. 
7284 
4686 
5233 
1970 
4347 
3756 
7540 
5621 
5902 
5138 
5410 
5807
Mean 
S. D. 
n
2846
559
12
3527
732
12
5225
1490
12
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AUC VALUES (Trapezoidal Method)
DRUG: TRIAMTERENE 
AUC ng.h/ml
Subject 0-4 hr. 0-6 hr. 0-24 hr.
1 60 67 67
2 135 144 144
3 63 63 63
4 63 63 63
5 220 262 274
6 109 123 128
7 97 102 102
8 110 121 121
9 91 100 100
10 84 89 89
11 122 138 144
12 118 132 138
Mean 106 117 119
S. D. 44 54 57
n 12 12 12
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OBSERVED Cmax AND Traax VALUES
Drug: Xipamide and Trirexan
XIPAMIDE TRIREXAN .
Subj. No.
Cmax Tmax Cmax Tmax
1 1047 3. 0 1208 1.5
2 1320 0.5 1334 0.5
3 1316 1. 0 1329 1. 0
4 1001 0.5 568 2. 0
5 1570 0.5 1279 1.5
6 1115 0.5 1138 1. 0
7 909 2. 0 1414 0.5
8 1608 1. 0 1424 1. 0
9 1279 1. 0 1377 1. 0
10 933 1.5 1042 2. 0
11 1464 0.5 1275 1. 0
12 1098 1.5 1051 1.5
Mean 
Std.Dev. 
N
1222
241
12
1. 13 
0. 77 
12
1203
238
12
1. 21 
0. 50 
12
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DRUG: TRIREXAN (TRIAMTERENE)
AUC np;. h/ml
Subject 0-4_hr. 0-6 hr. 0-24 hr.
AUQ_VALUES (Trapezoidal Method)
1 57 57 57
2 108 120 120
3 99 107 107
4 54 70 77
5 215 261 305
6 96 103 127
7 91 96 96
8 103 114 114
9 108 113 113
10 78 95 137
11 153 165 165
12 106 116 116
Mean 106 118 128
S. D. 43 52 62
n 12 12 12
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PAIRED T-TEST : AUC VALUES CTRIAMTEREHE/TRIRBXAN)
TIME PERIODS
0-4 hour 0-6 hour 0
Mean Triamterene <30mg> 106 117
Trirexan* 106 118
Diff. between means - 1
Standard Error 5 6
t-value probability 0.950 0.847
* Trirexan containing 30mg triamterene.
24 hour 
119 
128
9
7
0. 251
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FAIRED T-TEST j_ AUC VALUES (XIPAMIDE/TRIREXAN)
Mean Xipamide<lOmg) 
Trirexan*
0-4 hour 
2721 
2846
TIME PERIODS 
0-6 hour 
3467 
3527
Diff. between means 
Standard Error
125
120
60
126
t-value probability 0. 320 0. 645
^Trirexan containing lOmg xipamide.
-24 hour 
5510 
5225
286
268
0. 310
138
RESULTS
RESULTS
Xipamide
The mean AUC values after dosing with xipamide and Trirexan 
were 5554 and 5255 ng.h/ml respectively, and the mean 
elimination half-life values were 3.82 and 3.14 h. The mean 
observed Cmax values were 1222 and 1203 ng/ml, and the mean 
observed Tmax values were 1.13 and 1.21 h. These mean values 
were not significantly different (p > 0.05).
b) Triamterene
The mean AUC values post dosing with triamterene and Trirexan 
were (138 and 145 ng.h/ml respectively, and the mean elimination 
half-life values were 1.28 and 1.47 h. The mean observed Cmax 
values were 54 and 59 ng/ml, and the mean observed Tmax values 
were 0.79 and 0.75 h. These mean values were not significantly 
different (p > 0.05).
In summary, the pharmacokinetic profiles of xipamide and 
triamterene obtained when administered as a single oral dose in 
a fixed combination (Trirexan), were similar to the 
corresponding profiles obtained when each drug was administered 
alone.
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SAMPLE CHROMATOGRAMS
SAMPLE CHROMATOGRAMS
SUBJECT 1 18.0 AND 24.0 hrs. post dosing
AND 25 ng/ml Standard
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SAMPLE CHROMATOGRAMS
SUBJECT 4 , 6.0, AND 12.0 hi dosing
A \ \ \ j v  -
143
■ ! ■ » .  2 . 0  A W  3 . 0  h r s . p o s t  d o s ln s
144
SAMPLE CHROMATOGRAMS STANDARDS 
0 AND 5 AND 10 (ng/ml)
145
SAMPLE CHROMATOGRAMS STANDARDS
50 AND 100 AND QC 25 (ng/ml)
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SAMPLE CHROMATOGRAMS
SUBJECT 3 0.5 ,1.0 AND 1.5 hrs. post dosing
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SAMPLE CHROMATOGRAMS
SUBJECT 3 2.0, 3.0 AND 6.0 hrs. post dosing
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SAMPLE CHROMATOGRAMS
SUBJECT 3 8.0,10.0 AND 12.0 hrs. post dosing
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SAMPLE CHROMATOGRAMS
SUBJECT 3 18.0, AHD 24.0 hrs. po^t dosing
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SAMPLE CHROMATOGRAMS
STANDARDS 100 , 250 AND 500 ng/ml
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SAMPLE CHROMATOGRAMS 
STANDARDS 1000 , and 2500 ng/ml
: a
152
